RxDoctor Payments Data

Joella Lambert, MD

Hospitalist · Oxford, MSNPI 1316574585

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $213, more than ten times the $19 reported in 2020. That places this record below the midpoint for hospitalist clinicians in MS, where the typical reported total is $523.

$587in general payments, 2019–2025

Across 31 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$112
  • Boehringer Ingelheim$110
  • Merck$104
  • Novartis$74
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$58
  • Amgen$29
  • plus $101 from 5 others

What the payments were for

  • Food & beverage$587100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$587 in reported general payments places this provider in the 50th percentile of 102 hospitalist providers in Mississippi.

See all hospitalist providers in Mississippi

Medicare billing

Part B allowed, 2024
$149,400
Medicare patients
579
Services billed
1,352

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin12$6,618
EliquisApixaban11$6,462
Cefdinir32$293
Nitroglycerin15$278
Potassium Chloride20$268
Midodrine Hcl11$206
Hydralazine Hcl16$114
Carvedilol35$107
Ondansetron OdtOndansetron14$105
Amiodarone Hcl14$102
Prednisone17$100
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen27$93
Pantoprazole Sodium21$86
Atorvastatin Calcium28$76
Metoprolol Succinate14$71

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$110$6,61812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 102 hospitalist providers in Mississippi.

Other hospitalist in Oxford

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →